Edwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.64, in-line with the analyst estimate of $0.64. Revenue for the quarter came in at $1.53 billion versus the consensus estimate of $1.5 billion.

GUIDANCE:

Edwards Lifesciences sees Q1 2024 EPS of $0.62-$0.66, versus the consensus of $0.67. Edwards Lifesciences sees Q1 2024 revenue of $1.53-1.61 billion, versus the consensus of $1.563 billion.

Edwards Lifesciences sees FY2024 EPS of $2.70-$2.80, versus the consensus of $2.75. Edwards Lifesciences sees FY2024 revenue of $6.3-6.6 billion, versus the consensus of $6.475 billion.

The company is confident in the sales guidance it provided at the December 2023 investor conference for all product groups. In addition, as a result of the earlier than expected U.S. approval of EVOQUE, management now expects full year 2024 TMTT sales at the higher end of the previous $280 to $320 million guidance range.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.